This press release shows a phase 3, randomized, double-blind, placebo-controlled trial to evaluate the efficacy and safety of a three-day course of remdesivir in the outpatient setting. .

This study, showed a statistically significant 87% reduction in risk for the composite primary endpoint of COVID-19 related hospitalization or all-cause death by day 28 compared with placebo (0.7% versus 5.3%). It is to note that no deaths occurred in either group.

This study shows that the best use of remdesivir may be to reduce hospitalization due to COVID-19. In order to see a mortality benefit a much larger study is needed.

Any information or statement present in this post does not replace your health care provider’s advice or treatment. This blog does not provide medical advice, prescribe medications or therapies, or diagnose conditions, it only expresses an opinion. If you have a health-related question or condition, confer with your healthcare provider.